YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
On August 4, Arvinas Inc. (NASDAQ:ARVN) reported second-quarter 2026 financial results and a corporate update that doubled as one of the more consequential updates in the company's history. The clinical-stage biotech disclosed the first-ev…
Kymera Therapeutics KYMR is leveraging targeted protein degradation, a next-generation small-molecule therapeutic modality that harnesses the body's natural cellular recycling system to selectively eliminate disease-causing proteins. The c…
Earnings Call Insights: Arvinas (ARVN) Q2 2026 MANAGEMENT VIEW * “We’ve reached 3 significant strategic milestones since the start of the year, beginning with the first-ever FDA approval of a PROTAC degrader, VEPPANU,” said CEO Randy Teel.…
Major earnings expected before the bell on Tuesday include: * Pfizer (PFE [https://seekingalpha.com/symbol/PFE]) * Energy Transfer LP (ET [https://seekingalpha.com/symbol/ET]) * Merck & Co. (MRK [https://seekingalpha.com/symbol/MRK]) * Cat…
* Arvinas (ARVN [https://seekingalpha.com/symbol/ARVN]) is scheduled to announce Q2 earnings results on Tuesday, August 4th, before market open. * The consensus EPS Estimate is -$0.28 [https://seekingalpha.com/symbol/ARVN/earnings/estimate…
Kymera Therapeutics KYMR is leveraging targeted protein degradation (TPD), a next-generation small-molecule therapeutic modality that harnesses the body's natural cellular recycling system to selectively eliminate disease-causing proteins.…
SOUTH SAN FRANCISCO, Calif., June 16, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the closing of its license agreeme…
Twist Bioscience (TWST) shares ended the last trading session 9.3% higher at $74.05. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 24.6% gain o…
Arvinas Inc. NEW HAVEN, Conn., May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will…
NEW HAVEN, Conn., May 18, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced that employees across Con…
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Rigel Pharmaceuticals Inc.(NASDAQ:RIGL) stock is trading higher on Tuesday as the company is entering an exclusive global licensing agreem…
Rigel Pharmaceuticals has entered an exclusive global license agreement with Arvinas and Pfizer to develop, manufacture and commercialize VEPPANU (vepdegestrant), the first FDA-approved oral PROTAC for adults with ER+/HER2-, ESR1-mutated a…
Arvinas Inc(NASDAQ:ARVN) reported downbeat results for the first quarter on Tuesday. The company posted quarterly losses of 90 cents per share which missed the analyst consensus estimate of losses of 87 cents per share. The company reporte…
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. BMO Capital raised the price target for Nextpower…
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Pfizer (NYSE:PFE) and Arvinas have transferred global development and commercialization rights fo…
Arvinas logo Key Points Interested in Arvinas, Inc.? Here are five stocks we like better. VEPPANU’s FDA approval was the quarter’s biggest milestone, with CEO Randy Teel calling it the first approval of a heterobifunctional PROTAC degrader…
(RTTNews) - Rigel Pharmaceuticals, Inc. (RIGL) on Tuesday said it has entered into a global license agreement with Arvinas, Inc. (ARVN) and Pfizer Inc. (PFE) to develop, manufacture and commercialize beast cancer treatment Veppanu. Veppanu…
VEPPANU has a novel mechanism of action, is the first and only FDA-approved PROTAC and has the potential to become an important new treatment option for adult patients with 2L+ ER+/HER2-, ESR1-mutated mBC Pivotal Phase 3 VERITAC-2 clinical…
Arvinas Inc. – Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for additional $320 million in development, regulatory, and commercial milestones and tiered royalites on net sales – NEW HAVEN, Con…
Major earnings expected before the bell on Tuesday include: * JD.com (JD [https://seekingalpha.com/symbol/JD]) * Sea Limited (SE [https://seekingalpha.com/symbol/SE]) * D-Wave Quantum (QBTS [https://seekingalpha.com/symbol/QBTS]) * Lithium…
NEW HAVEN, Conn., May 05, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced that management will review first quarte…
Blood-based test enables identification of patients eligible for targeted treatment with VEPPANU™ Approval marks Guardant’s third ESR1 companion diagnostic FDA approval to help guide timely treatment decisions for patients with advanced br…
[US Food and Drug Administration (FDA)] The U.S. Food and Drug Administration on Friday approved vepdegestrant, a breast cancer therapy developed by Pfizer (PFE [https://seekingalpha.com/symbol/PFE]) and Arvinas (ARVN [https://seekingalpha…
Arvinas Inc. – VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader – – Approval received in advance of FDA-assigned PDUFA date of June 5, 2026; Arvinas and Pfizer remain on track to announce se…
– VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader – – Approval received in advance of FDA-assigned PDUFA date of June 5, 2026; Arvinas and Pfizer remain on track to announce selection of a…
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. The Arvinas fair value estimate has shifted from US$14.56 to US$14.88 per share, a small move that still matters if you are…
Arvinas, Inc.ARVN shares soared 6.9% in the last trading session to close at $11.33. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 20.7% loss over the past fo…
Arvinas Inc. (NASDAQ:ARVN) is one of the best cancer stocks to invest in now. On February 24, Arvinas Inc. (NASDAQ:ARVN) delivered solid fourth-quarter and full-year results that affirmed progress across pipeline development.Arvinas, Inc.…
* Arvinas (ARVN [https://seekingalpha.com/symbol/ARVN]) is scheduled to announce Q4 earnings results on Tuesday, February 24th, before market open. The consensus EPS Estimate is -$0.57 [https://seekingalpha.com/symbol/ARVN/earnings/estimat…
NEW HAVEN, Conn, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate i…
Feb 12 (Reuters) - Indian textile maker Welspun Living, which exports to global retailers including Walmart and Tesco, posted a slump in its quarterly profit on Thursday, as a U.S. tariff-triggered slowdown in exports squeezed its margin…
The PROTAC market is experiencing rapid growth, driven by rising interest in targeted protein degradation as a next-generation therapeutic approach. Expanding oncology pipelines with drugs in clinical trials such as vepdegestrant (Arvinas…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial to evaluate ARV-393 plus glofitamab as a chemotherapy-free combination approach in diffuse large B-cell lymphoma (DLBCL); initiation expected in 2026 –…
NEW HAVEN, Conn., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Noah Berkowitz, M.D., Ph.D.,…
NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that multiple abstracts on vepdeg…
Arvinas Inc. NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that multiple abstra…